Related Experiment Video
Updated: Jun 17, 2026
06:39
Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome
Published on: October 3, 2018
Azacitidine in lower-risk myelodysplastic syndromes
1UF Ematologia, Azienda Ospedaliero-Universitaria (AOU) Careggi, Università degli Studi di Firenze, Florence, Italy. santini@unifi.it
Leukemia Research
|December 17, 2009
Summary
Azacitidine shows promise for lower-risk myelodysplastic syndromes (MDS). Studies indicate improved response rates and overall survival (OS) in these patients, suggesting its effectiveness beyond higher-risk MDS.
Area of Science:
- Hematology
- Oncology
- Clinical Pharmacology
Background:
- Myelodysplastic syndromes (MDS) are a group of clonal hematopoietic stem cell disorders.
- Higher-risk MDS patients benefit from azacitidine, but its role in lower-risk MDS is less defined.
- Conventional care regimens for lower-risk MDS have limited efficacy.
Purpose of the Study:
- To review available data on azacitidine treatment in lower-risk myelodysplastic syndromes (MDS).
- To evaluate the efficacy and feasibility of azacitidine in this patient population.
Main Methods:
- Review of Phase III, Phase II, and retrospective studies involving azacitidine in lower-risk MDS.
- Analysis of overall response rate (ORR), overall survival (OS), hematological improvement, and transfusion independence.
Main Results:
- A Phase III study showed a 60% ORR and longer median OS (44 vs 27 months) with azacitidine in lower-risk MDS.
- Phase II studies reported approximately 50% hematological improvement and high rates of transfusion independence.
- Retrospective data indicated a 52% ORR in patients receiving at least 4 cycles of azacitidine.
Conclusions:
- Azacitidine demonstrates feasibility and effectiveness in treating lower-risk MDS patients.
- The agent offers significant benefits in response rates and survival for this group.
- Preliminary combination therapy data warrants further cautious investigation.